アブストラクト
| Title | 非アルコール性脂肪性肝炎 (NASH) |
|---|---|
| Subtitle | 特集 / 糖尿病診療の最前線 糖尿病の関連病態 |
| Authors | 国府島庸之 |
| Authors (kana) | |
| Organization | 九州大学大学院医学研究院病態制御内科学(第三内科) |
| Journal | 臨牀と研究 |
| Volume | 98 |
| Number | 1 |
| Page | 55-60 |
| Year/Month | 2021 / 1 |
| Article | 報告 |
| Publisher | 大道学舘出版部 |
| Abstract | 「はじめに」我が国では, 食生活の欧米化と生活習慣の変化のため肥満人口の増加が顕著で, メタボリックシンドローム・生活習慣病の罹患率は増加の一途をたどっている. 肝臓の脂肪化は飲酒, 薬物, 内分泌疾患, 中毒, 代謝異常など様々原因により起こるが, 肥満, 糖尿病, 脂質異常症等を背景にメタボリックシンドロームの肝臓での表現型として脂肪性肝障害を来したものが非アルコール性脂肪性肝疾患(non-alcoholic fatty liver disease:NAFLD)で, NAFLDのうち肝実質細胞の壊死, 炎症所見を伴う進行性の慢性疾患が非アルコール性脂肪性肝炎(non-alcoholic steatohepatitis:NASH)と考えられる. NASH症例の一部は肝硬変や肝細胞癌を発症するが, 近年の糖尿病を含めた生活習慣病の増加に伴って, NASHを基礎とした肝細胞癌は更に増加すると考えられ, 糖尿病の関連病態として解決すべき重要な問題である. |
| Practice | 臨床医学：一般 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
参考文献
- 1) Ludwig, J. et al.:Nonalcoholic steatohepatitis:Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc, 55(7):434-438,1980.
- 2) Schaffner, F. et al.:Nonalcoholic fatty liver disease. Prog Liver Dis, 8:283-298,1986.
- 3) 日本肝臓学会編:NASH NAFLDの診療ガイドライン2015. 文光堂, 東京, 2015.
- 4) Matteoni, C.A. et al.:Nonalcoholic fatty liver dis-ease: a spectrum of clinical and pathological severity. Gastroenterology, 116(6):1413-1419,1999.
- 5) Brunt, E.M. et al.:Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol, 94(9):2467-2474,1999.
残りの23件を表示する
- 6) Kleiner, D.E. et al.:Design and validation of a histo-logical scoring system for nonalcoholic fatty liver disease. Hepatology, 41(6):1313-1321,2005.
- 7) Kojima, S. et al.:Increase in the prevalence of fatty liver in Japan over the past 12 years:analysis of clinical background. J Gastroenterol, 38(10):954-961,2003.
- 8) Jimba, S. et al.:Prevalence of non-alcoholic fatty dis-ease and its association with impaired glucose metabo-lism in Japanese adults. Diabet Med, 22(9):1141-1145,2005.
- 9) 堀田饒ほか:アンケート調査による日本人糖尿病の死因-1991〜2000年の10年間, 18,385名での検討-. 糖尿病, 50(1):47-61,2007.
- 10) 中村二郎ほか:アンケート調査による日本人糖尿病の死因-2001〜2010年の10年間, 45,708名での検討-. 糖尿病, 59(9):667-684,2016.
- 11) Eguchi, Y. et al.:Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol, 47(5):586-595,2012.
- 12) Wong, V.W. et al.:Noninvasive biomarkers in NAFLD and NASH-current progress and future promise. Nat Rev Gastroenterol Hepatol, 15(8):461-478,2018.
- 13) Kohjima, M. et al.:Re-evaluation of fatty acid metabo-lism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med, 20(3):351-358,2007.
- 14) Matsuzaka, T. et al.:Elovl6 promotes nonalcoholic steatohepatitis. Hepatology, 56(6):2199-2208,2012.
- 15) Kohjima, M. et al.:SREBP-1c, regulated by the insu-lin and AMPK signaling pathways, plays a role in non-alcoholic fatty liver disease. Int J Mol Med, 21(4):507-511,2008.
- 16) Kubota, N. et al.:Differential hepatic distribution of insulin receptor substrates causes selective insulin re-sistance in diabetes and obesity. Nat Commun, 6:12977,2016.
- 17) Higuchi, N. et al.:Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol Res, 38(11):1122-1129,2008.
- 18) Nakamuta, M. et al.:Impact of cholesterol metabo-lism and the LXRalpha-SREBP-1c pathway on nonalco-holic fatty liver disease. Int J Mol Med, 23(5):603-608,2009.
- 19) Kamada, Y. et al.:Adipocytokines and liver disease. J Gastroenterol, 43(11):811-822,2008.
- 20) Rolo, A.P. et al.:Role of oxidative stress in the patho-genesis of nonalcoholic steatohepatitis. Free Radic Biol Med, 52(1):59-69,2012.
- 21) Tilg, H. et al.:Evolution of inflammation in nonalco-holic fatty liver disease:multiple parallel hits hypothe-sis. Hepatology, 52(5):1836-1846,2010.
- 22) Imajo, K. et al.:Hyperresponsivity to low-dose endo-toxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab, 16(1):44-54,2012.
- 23) Romeo, S. et al.:Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genetics, 40(12):1461-1465,2008.
- 24) Speliotes, E.K. et al.:Genome-wide association analy-sis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLos Genet, 7(3):1-14,2011.
- 25) Friedman, S.L. et al.:Mechanisms of NAFLD devel-opment and therapeutic strategies. Nat Med, 24(7):908-992,2018.
- 26) Itoh, M. et al.:Melanocortin-4 receptor-deficient mice as a novel mouse model of non-alcoholic steatohepatitis. Am J Pathol, 179(5):2454-2463,2011.
- 27) Itoh, M. et al.:Hepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humans, PLoS ONE, 8(12):e82163,2013.
- 28) Musso, G. et al.:Non-alcoholic steatohepatitis:emerg-ing molecular targets and therapeutic strategies. Nat Rev Drug Discov, 15(4):247-274,2016.
